Senior Management Changes at Lilly

Effective January 1, Dave Ricks, president of Lilly USA, will succeed Bryce D. Carmine as senior vice president and president of Lilly Bio-Medicines. Mr. Ricks’ responsibilities will include the U.S., Japan, and Europe. Bio-Medicines encompasses the therapeutic areas of neuroscience, cardiovascular, autoimmunity, musculoskeletal, and urology.

Maria Crowe, senior vice president for global drug product manufacturing, will succeed Frank Deane, Ph.D. as president of manufacturing operations, also effective January 1. Ms. Crowe was previously general manager of manufacturing sites in Ireland and Puerto Rico. As head of manufacturing operations, she will lead a network of 22 sites in 13 countries and will have responsibility for Lilly’s global contract manufacturing organization.

Mr. Carmine’s career at Lilly spans 36 years. He has led Lilly Bio-Medicines since its creation in 2009. Dr. Deane, who’s been at Lilly for 33 years, has led global manufacturing operations since 2007. Previously, both held numerous high-level leadership posts around the globe.

John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, described Carmine and Deane as “pillars of the company who have had a lasting, worldwide impact on our people and our business. We’re grateful for their dedicated service.”

Additionally, Alex Azar is being promoted to president of Lilly USA. Mr. Azar has been vice president of U.S. managed healthcare services and PR since 2009. He joined the company in 2007 as senior vice president of Lilly’s global corporate affairs and communications division.

“We’ll certainly miss Bryce and Frank and the extraordinary leadership they provided,” Dr. Lechleiter said. “At the same time, we’re very fortunate to have talented leaders who are well-prepared and ready to step into these critical roles.”